查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胃食管反流药物全球市场规模调查和预测，按药物类型（抗酸剂、H2 受体阻滞剂、质子泵抑製剂 (PPI)、促动力药），区域分析，2022-2029 年
市场调查报告书
商品编码
1258052

胃食管反流药物全球市场规模调查和预测，按药物类型（抗酸剂、H2 受体阻滞剂、质子泵抑製剂 (PPI)、促动力药），区域分析，2022-2029 年

Global Gastroesophageal Reflux Disease Therapeutics Market Size study & Forecast, by Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents), and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021 年全球胃食管反流药物市场价值 51.8 亿美元，在预测的 2022-2029 年预测期内以超过 1.76% 的健康增长率增长。

胃食管反流病 (GERD) 是一种慢性疾病，胃酸和其他内容物反流回食道，导致胃灼热、反流和吞嚥困难等症状。 称为下食管括约肌 (LES) 的一圈肌肉通常会阻止胃内容物回流到食道。我会逃跑。 GERD 可能由多种因素引起，包括肥胖、怀孕、某些药物和食管裂孔疝（胃的一部分被向上推过横膈膜进入胸部的情况）。 GERD 的治疗通常包括改变生活方式（例如避免不良食物、减肥和戒烟）和减少胃酸量的药物。 严重的病例可能需要手术来加强 LES 或修復裂孔疝。 GERD 药物的目标是减少胃酸量并减轻症状的严重程度。 市场需求主要受人口老龄化、患者和医疗保健提供者对 GERD 及其相关症状的认识提高、早期诊断和治疗的推动，这反过来又推动了对 GERD 疗法的需求。它是由以下因素引起的：

此外，GERD 的患病率在世界范围内呈上升趋势，这主要是由于饮食习惯的改变、肥胖率上升和人口老龄化所致。 因此，寻求治疗的患者数量不断增加，推动了对 GERD 疗法的需求。 根据美国国家医学图书馆的数据，2019 年全球有 7.8395 亿 GERD 患者，因此这些因素预计将进一步增加全球市场对 GERD 疗法的需求。 此外，GERD 治疗的重大技术进步，如微创手术和内窥镜治疗，正在推动对这些治疗的需求。需求正在增加。 这为公司提供了在 GERD 治疗市场扩大其 OTC 药物的机会，这将在未来几年提供市场增长机会。 然而，不良的药物管道和患者死亡率限制了 2022-2029 年预测期内的市场增长。

全球胃食管反流药物市场研究考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于人口增长导致 GERD 治疗的使用增加，北美在销售方面占据市场主导地位。 另一方面，预计亚太地区将在预测期内以最高增长率增长。 GERD 患病率上升、目标市场治疗知识增加以及主要市场进入者产品线多样化等因素正在推动预测期内的市场增长。

本研究的目的是阐明近年来各个细分市场和国家/地区的市场规模，并预测未来几年的市场规模。 该报告旨在捕捉被调查国家工业的定性和定量方面的情况。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的潜在微观市场机会，以及对主要参与者的竞争格局和产品供应的深入分析。 .

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年各细分市场的全球市场估计和预测
    • 2019-2029 年按地区划分的胃食管反流药物市场
    • 2019-2029 年按药物类型划分的胃食管反流药物市场
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章胃食管反流药物全球市场的定义和范围

  • 调查目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 本次调查涵盖的年份
  • 货币兑换率

第三章全球胃食管反流药物市场动态

  • 胃食管反流药物市场影响分析 (2019-2029)
    • 市场驱动力
      • 老年人口增加
      • 提高对 GERD 药物的认识
      • GERD 的患病率越来越高
    • 市场挑战
      • 药物管线不佳，患者死亡率高
    • 市场机会
      • GERD 治疗方案的技术进步
      • 对非处方 (OTC) GERD 治疗的需求不断增长

第四章全球胃食管反流药物市场分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 主要投资机会
  • 关键成功策略
  • 业内人士的前景
  • 分析师的建议和结论

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章全球胃食管反流药物市场：按药物类型分类

  • 市场概况
  • 全球胃食管反流药物市场：按药物类型、性能-潜力分析
  • 2019-2029 年按药物类型划分的胃食管反流药物市场估计和预测
  • 胃食管反流药物市场细分分析
    • 抗酸剂
    • H2 受体阻滞剂
    • 质子泵抑製剂 (PPI)
    • 促动力剂

第 7 章全球胃食管反流药物市场：区域分析

  • 胃食管反流药物市场，按地区划分的市场概况
  • 北美
    • 美国
      • 2019-2029 年按药物类型估算和预测
    • 加拿大
  • 欧洲胃食管反流药物市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲
  • 亚太地区胃食管反流药物市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲胃食管反流药物市场概况
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 世界其他地区

第 8 章衝突信息

  • 主要市场策略
  • 公司简介
    • 葛兰素史克公司
      • 关键信息
      • 概览
      • 财务（仅当数据可用时）
      • 产品概览
      • 近期趋势
    • Pfizer, Inc.
    • Sanofi S.A.
    • Johnson & Johnson Pvt. Ltd.
    • Glenmark Pharmaceuticals Ltd
    • Camber Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited.
    • Ironwood Pharmaceuticals, Inc.
    • Phathom Pharmaceuticals, Inc.
    • Adcock Ingram

第9章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查的特点
  • 调查先决条件

Global Gastroesophageal Reflux Disease Therapeutics Market is valued at approximately USD 5.18 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 1.76% over the forecast period 2022-2029. Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid and other contents flow back up into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Normally, a muscular ring called the lower esophageal sphincter (LES) prevents stomach contents from flowing back into the esophagus, but in GERD, this ring is weakened or relaxed, allowing stomach acid and other contents to escape into the esophagus. GERD can be caused by a variety of factors, including obesity, pregnancy, certain medications, and a hiatal hernia (a condition in which part of the stomach pushes up into the chest through the diaphragm). Treatment for GERD typically involves lifestyle modifications (such as avoiding trigger foods, losing weight, and quitting smoking) and medications to reduce the amount of acid in the stomach. In severe cases, surgery may be necessary to strengthen the LES or repair a hiatal hernia. The goal of GERD therapeutics is to reduce the amount of acid in the stomach and decrease the severity of symptoms. The market demand is primarily driven by the factors such as the increasing geriatric population, coupled with increasing awareness of GERD and its associated symptoms among patients and healthcare providers, which is leading to earlier diagnosis and treatment which in turn is driving the demand for GERD therapeutics.

In addition, the increasing prevalence of GERD is increasing worldwide, primarily due to changing dietary habits, increasing obesity rates, and an aging population. This has resulted in a growing patient population seeking treatment, which is driving the demand for GERD therapeutics. The National Library of Medicine reported that globally, there were 783.95 million GERD cases in 2019, thus, in turn, these factors are expected to escalate the demand for GERD Therapeutics in the global market. Furthermore, there have been significant technological advancements in GERD treatment options, such as minimally invasive surgery and endoscopic treatments, which are driving the demand for these treatments, as well as there is increasing demand for OTC GERD medications due to their easy availability and affordability. This presents an opportunity for companies to expand their OTC offerings in the GERD therapeutics market presenting lucrative opportunities for market growth over the forthcoming years. However, poor medication pipeline and patient mortality are restricting the market growth over the forecast period of 2022-2029.

The key regions considered for the Global Gastroesophageal Reflux Disease Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing use of GERD therapeutics as a result of the disease's rising incidence in the local population. Whereas, Asia Pacific is also expected to grow at the highest growth rate over the forecasting period. Factors such as rising incidences of the ailment, rising knowledge of its treatment among the target market, and rising emphasis on the part of major market participants to diversify their product lines are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Johnson & Johnson Pvt. Ltd.
  • Glenmark Pharmaceuticals Ltd
  • Camber Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Ironwood Pharmaceuticals, Inc.
  • Phathom Pharmaceuticals, Inc.
  • Adcock Ingram

Recent Developments in the Market:

  • In July 2022, Adcock Ingram introduced dexlansoprazole modified release, a novel proton pump inhibitor. Professor Ronnie Fass of Ohio's Case Western Reserve University delivered the event's keynote address (United States). Prof. Fass is a recognised authority in gastroesophageal reflux disease and its diagnosis and treatment (GERD).
  • In June 2022, Glenmark Pharmaceuticals Ltd acquired the authorized generic versions of some over-the-counter medications from Wockhardt Ltd in the United States. The company's wholly-owned subsidiary Glenmark Pharmaceuticals Inc. in the USA has acquired the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, as well as Lansoprazole delayed-release capsules USP, 15 mg, a medication used to treat indigestion, heartburn, and acid reflux.
  • In March 2022, Phantom Pharmaceuticals' FDA-approved medication Vonoprazan, which was created for the treatment of GERD, is now offered over the counter in Japan and other Asian nations. Also, due to the rising demand for GERD therapies in the region, a number of firms have increased their presence in Asia.

Global Gastroesophageal Reflux Disease Therapeutics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

  • Antacids
  • H2 Receptor Blockers
  • Proton Pump Inhibitors (PPIs)
  • Pro-kinetic agents

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • ROLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Gastroesophageal Reflux Disease Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Gastroesophageal Reflux Disease Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics

  • 3.1. Gastroesophageal Reflux Disease Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing geriatric population.
      • 3.1.1.2. Rising awareness towards GERD Therapeutics.
      • 3.1.1.3. Increasing prevalence of GERD.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Poor medication pipeline and patient mortality.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Technological advancements in GERD treatment options.
      • 3.1.3.2. Increasing demand for over-the-counter (OTC) GERD medications

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Gastroesophageal Reflux Disease Therapeutics Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Gastroesophageal Reflux Disease Therapeutics Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Gastroesophageal Reflux Disease Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Antacids
    • 6.4.2. H2 Receptor Blockers
    • 6.4.3. Proton Pump Inhibitors (PPIs)
    • 6.4.4. Pro-kinetic agents

Chapter 7. Global Gastroesophageal Reflux Disease Therapeutics Market, Regional Analysis

  • 7.1. Gastroesophageal Reflux Disease Therapeutics Market, Regional Market Snapshot
  • 7.2. North America Gastroesophageal Reflux Disease Therapeutics Market
    • 7.2.1. U.S. Gastroesophageal Reflux Disease Therapeutics Market
      • 7.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
    • 7.2.2. Canada Gastroesophageal Reflux Disease Therapeutics Market
  • 7.3. Europe Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.3.1. U.K. Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.2. Germany Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.3. France Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.4. Spain Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.5. Italy Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.6. Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
  • 7.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.4.1. China Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.2. India Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.3. Japan Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.4. Australia Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.5. South Korea Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.6. Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
  • 7.5. Latin America Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.5.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.2. Mexico Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.3. Rest of Latin America Gastroesophageal Reflux Disease Therapeutics Market
  • 7.6. Rest of The World Gastroesophageal Reflux Disease Therapeutics Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. GlaxoSmithKline plc
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Pfizer, Inc.
    • 8.2.3. Sanofi S.A.
    • 8.2.4. Johnson & Johnson Pvt. Ltd.
    • 8.2.5. Glenmark Pharmaceuticals Ltd
    • 8.2.6. Camber Pharmaceuticals, Inc.
    • 8.2.7. Takeda Pharmaceutical Company Limited.
    • 8.2.8. Ironwood Pharmaceuticals, Inc.
    • 8.2.9. Phathom Pharmaceuticals, Inc.
    • 8.2.10. Adcock Ingram

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Gastroesophageal Reflux Disease Therapeutics Market, report scope
  • TABLE 2. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 5. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 16. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 69. List of primary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Gastroesophageal Reflux Disease Therapeutics Market, research methodology
  • FIG 2. Global Gastroesophageal Reflux Disease Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Gastroesophageal Reflux Disease Therapeutics Market, key trends 2021
  • FIG 5. Global Gastroesophageal Reflux Disease Therapeutics Market, growth prospects 2022-2029
  • FIG 6. Global Gastroesophageal Reflux Disease Therapeutics Market, porters 5 force model
  • FIG 7. Global Gastroesophageal Reflux Disease Therapeutics Market, pest analysis
  • FIG 8. Global Gastroesophageal Reflux Disease Therapeutics Market, value chain analysis
  • FIG 9. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Gastroesophageal Reflux Disease Therapeutics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Gastroesophageal Reflux Disease Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable